EGFR and non-small cell lung carcinoma: Moreover, amivantamab has already been approved by the FDA and EMA for EGFR exon 20 insertion mutations NSCLC, and it is currently in clinical research for patients with EGFR+ NSCLC progressing on TKIs (MARIPOSA-2 and PALOMA-3) [123,124].